|
|
|
| Analysis of 125 adverse drug reaction cases caused by anti-tuberculosis drugs |
| LI Hui ZHANG Hongliang YANG Tianyan HUANG Zhenguang LIU Taotao WEI Fang |
| Department of Pharmacy, the First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning 530021,China |
|
|
|
Abstract Objective To analyze the adverse drug reactions (ADR) caused by the anti-tuberculosis drugs, and to provide the reference for the rational use of the tuberculosis. Methods A retrospective study was conducted to collect 125 ADR cases of anti-tuberculosis drugs reported by the First Affiliated Hospital of Guangxi Medical University from 2012 to 2018. The gender, age, occurrence time of ADR, types of suspected drugs, route of administration, ADR related systems and clinical manifestations in the reports were statistically analyzed. Results ADR reports were mainly male patients, accounting for 64.80%; most ADRs occurred within 30 days after administration, accounting for 96.80%; the suspicious drugs causing ADR were Isoniazid Tablets, Isoniazid Injection, Isoniazid Aminosalicylate Tablets, Rifampicin Tablets, Rifapentine Capsules, Pyrazinamide Tablets, Ethambutol Tablets, Streptomycin Sulfate for injection, Levofloxacin Capsules; the ADR caused by oral preparation was more, accounting for 96.80%; the main ADR caused by various antituberculosis drugs was urinary system damage, the main clinical manifestation was hyperuricemia, accounting for 45.60%, followed by hepatobiliary system damage, accounting for 21.60%; there were nine cases of severe ADR, accounting for 7.20%; 81 cases of ADR patients had good prognosis, accounting for 64.80%. Conclusion Clinical medical workers should pay attention to the monitoring and treatment of ADR from anti-tuberculosis drug, adjust the medication plan when necessary, and promote rational use of drug.
|
|
|
|
|
|
[1] 2018年全国法定传染病疫情概况[J].中华人民共和国国家卫生健康委员会公报，2019（3）：38-40.
[2] 王黎霞，成诗明，陈明亭，等.2010年全国第五次结核病流行病学抽样调查报告[J].中国防痨杂志，2012，34（8）：485-508.
[3] 卢萌，郑松柏.老年人抗菌药物的药动学特点[J].中国新药与临床杂志，2015，34（9）：652-656.
[4] 万书舟.对接受抗结核治疗的老年肺结核患者发生不良反应影响因素的研究[J].当代医药论丛，2018，16（14）：152-154.
[5] 黄维维.抗结核药物的不良反应及其处理[J].西部医学，2016，28（1）：137-140，145.
[6] Pichholiya M，Yadav AK，Luhadia SK，et al. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients [J]. Indian J Pharmacol，2016，48（5）：522-525.
[7] 石富国，古明，马世平.一线主要抗结核药不良反应分布特点文献分析[J].中国药物警戒，2011，8（7）：434-437.
[8] 肖桂荣，吴逢波，龙霞，等.抗结核药物不良反应管理的国内外指南综述分析[J].药物流行病学杂志，2014，23（7）：444-449.
[9] 冯红云，陈易新.4750例抗结核药品不良反应分析[J].中国药物警戒，2010，7（12）：751-754.
[10] 李祥，陶涛，王宏.广东省223例抗结核药不良反应报告分析[J].中国药房，2014，25（18）：1690-1692.
[11] 何涛，汪峰，唐武.抗结核药致药物性肝损伤危险因素的Logistic回归分析[J].中国药房，2016，27（12）：1626-1628.
[12] 抗结核药物性肝损伤诊治指南（2019年版）[J].中华结核和呼吸杂志，2019（5）343-356.
[13] 杨学敏，沈宝荣，刘鹏园，等.抗结核药致药物性肝损伤危险因素的Logistic回归分析[J].中国医院药学杂志，2019，39（1）：67-71.
[14] 马玉炯，张倩，兀威.抗结核药物不良反应研究进展[J].山东医药，2019，59（32）：111-113.
[15] 谭守勇.应重视抗结核药物性肝损伤的防治[J].中华结核和呼吸杂志，2019，42（5）：326-329.
[16] 朱春雾，王海南，袁继丽，等.445例药物性肝损伤的临床分析[J].临床肝胆病杂志，2018，34（2）：354-358.
[17] Falzon D，Jaramillo E，Schünemann HJ，et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis：2011 update [J]. Eur Respir J，2011，38（3）：516-528.
[18] The World Health Organization. Treatment of Tuberculosis：Guidelines [J]. Geneva：World Health Organization，2010.
[19] 杨铭，岳冀，李曦，等.利福平引起血小板减少14例临床分析[J].临床肺科杂志，2011，16（8）：1204.
[20] 王倩，陈津红，韩琴，等.441例抗结核药引起血液系统不良反应文献分析[J].中国药房，2008，19（5）：376-377 |
|
|
|
